-
Pandemic inevitably slows pharma M&A activity but appetite for deals remains
cphi-online
June 07, 2021
The initial outbreak of the COVID-19 pandemic delayed merger and acquisitions in the pharma sector, but evidence points to an uptick in activity because the rationale for sealing deals hasn’t changed
-
Avid Bioservices to Manufacture Zynlonta for ADC Therapeutics
contractpharma
May 26, 2021
Avid Bioservices Inc., a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing development and manufacturing services to biotechnology and pharmaceutical companies, will serve as ...
-
Zydus launches Ujvira (trastuzumab emtansine) for breast cancer treatment
expresspharma
May 25, 2021
Zydus Cadila launched Trastuzumab Emtansine, an antibody-drug conjugate (ADC) biosimilar and a drug for treating both early and advanced HER2 positive breast cancer, under the brand name ‘Ujvira’.
-
Sterling Pharma Appoints Stewart Mitchell as New Site Head
contractpharma
May 25, 2021
Sterling Pharma Solutions, a global CDMO, has appointed Stewart Mitchell as site head of its new antibody-drug conjugate (ADC) facility in Deeside, UK. Dr. Mitchell will lead the Deeside facility, and report to Kevin Cook ...
-
GeneQuantum Raises Hundreds of Millions RMB in Series C Funding
prnasia
May 19, 2021
GeneQuantum Healthcare (Suzhou) Co., Ltd. announced the completion of Series C fund raising of several hundreds of millions RMB.
-
Novasep Expands HPAPI Manufacturing Capacity
contractpharma
May 14, 2021
Novasep has expanded its highly potent active pharmaceutical ingredients (HPAPIs) manufacturing capabilities on its Le Mans, France site.
-
FDA Approves ADC Therapeutics' Zynlonta
contractpharma
May 08, 2021
ADC collaborated with CDMO Sterling Pharma Solutions to develop the cancer drug.
-
ADC Therapeutics gets USFDA nod for ZYNLONTA to treat relapsed or refractory diffuse large B-cell lymphoma
expresspharma
April 26, 2021
First and only CD19-targeted antibody drug conjugate (ADC) as a single-agent treatment for adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
-
Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC
prnasia
April 19, 2021
Peptron, Inc., a South Korea-based biotech company, and Qilu Pharmaceutical, a leading vertically integrated pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines announced that the companies ...
-
Sterling Pharma Solutions Acquires ADC Biotechnology
contractpharma
April 08, 2021
Global contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has acquired ADC Biotechnology, a UK-based bioconjugation development services business specializing in antibody drug conjugates (ADCs).